Pros | Beats FD returns for both 3Y & 5Y duration. | Among most bought funds within the category. Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | 3Y returns in the bottom 25% of the category. |
INDMoney rank | 4/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 6 Years | 12 Years | ||
Fund Size | 3074 Cr | 8114 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹100 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.6% | 0.91% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 32 | 41 | ||
Top 5 Holdings | Cipla Ltd (8.76%) Sun Pharmaceuticals Industries Ltd (7.96%) Cohance Lifesciences Ltd (7.9%) Ipca Laboratories Ltd (7.39%) Laurus Labs Ltd (6.07%) | Sun Pharmaceuticals Industries Ltd (12.29%) Lupin Ltd (7.26%) Divi's Laboratories Ltd (7.01%) Cipla Ltd (6.48%) Apollo Hospitals Enterprise Ltd (5.92%) | ||
No of Sectors | 2 | 1 | ||
Top 3 Sectors | Health (98.48%) Financial Services (1.52%) | Health (100%) | ||
Equity % | 97.95% | 99.47% | ||
Debt % | - | - | ||
P/E | 33.91 | 35.64 | ||
P/B | 5.05 | 5.65 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | 0.96% | 0.42% | ||
3-Month Return | -0.48% | -2.45% | ||
6-Month Return | 5.58% | 2.61% | ||
1-Year Return | 0.83% | 2.19% | ||
3-Year Return | 25.24% | 23.04% | ||
5-Year Return | 19.53% | 19.09% |
Sharpe | 1.1 | 0.95 | ||
Alpha | 2.77 | -0.12 | ||
Beta | 0.84 | 0.91 | ||
Standard Deviation | 14.69 | 15.23 | ||
Information Ratio | 0.1 | -0.44 |
Description | DSP Healthcare Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Chirag Dagli | Sailesh Raj Bhan,Kinjal Desai |